Early postoperative plasma circulating tumour DNA for molecular residue disease detection and recurrence risk evaluation in surgical non-small cell lung cancer

Clin Transl Med. 2024 Oct;14(10):e70056. doi: 10.1002/ctm2.70056.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Carcinoma, Non-Small-Cell Lung* / blood
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / surgery
  • Circulating Tumor DNA* / blood
  • Circulating Tumor DNA* / genetics
  • Female
  • Humans
  • Lung Neoplasms* / blood
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / surgery
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local* / blood
  • Neoplasm Recurrence, Local* / genetics
  • Risk Assessment / methods

Substances

  • Circulating Tumor DNA